Company Filing History:
Years Active: 2022
Title: Gaelle Herledan: Innovator in Multiple Myeloma Prognostics
Introduction
Gaelle Herledan is a notable inventor based in London, GB. She has made significant contributions to the field of medical research, particularly in the prognosis and treatment of multiple myeloma. Her innovative work has led to the development of methods that enhance patient care and treatment outcomes.
Latest Patents
Gaelle Herledan holds a patent for a prognostic method that determines the prognosis of multiple myeloma in patients. This method involves measuring the expression of BCMA in a sample. Additionally, her patent includes methods for treating multiple myeloma by administering an effective amount of an antigen binding protein that binds to BCMA. Furthermore, she has developed kits for measuring BCMA expression in samples, which are crucial for accurate diagnosis and treatment planning.
Career Highlights
Gaelle is currently associated with GlaxoSmithKline Intellectual Property Development Limited, where she continues to advance her research and innovations. Her work is pivotal in the ongoing fight against multiple myeloma, a complex and challenging form of cancer.
Collaborations
Gaelle collaborates with esteemed colleagues, including Danton Bounds and Jenny L Craigen. Their combined expertise fosters a productive environment for innovation and research in the medical field.
Conclusion
Gaelle Herledan's contributions to the field of multiple myeloma prognosis and treatment exemplify her dedication to improving patient outcomes through innovative research. Her work not only enhances our understanding of the disease but also paves the way for future advancements in cancer treatment.